|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-1-26
|
|
pubmed:abstractText |
Advanced hepatocellular carcinoma has a poor prognosis. In a Phase II clinical trial, two academic centers assessed irinotecan, a topoisomerase-1 inhibitor with broad spectrum clinical activity, in patients who had advanced hepatocellular cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
101-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11148565-Adult,
pubmed-meshheading:11148565-Aged,
pubmed-meshheading:11148565-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11148565-Camptothecin,
pubmed-meshheading:11148565-Carcinoma, Hepatocellular,
pubmed-meshheading:11148565-Diarrhea,
pubmed-meshheading:11148565-Fatigue,
pubmed-meshheading:11148565-Female,
pubmed-meshheading:11148565-Humans,
pubmed-meshheading:11148565-Liver Neoplasms,
pubmed-meshheading:11148565-Male,
pubmed-meshheading:11148565-Middle Aged,
pubmed-meshheading:11148565-Nausea,
pubmed-meshheading:11148565-Neutropenia,
pubmed-meshheading:11148565-Prognosis,
pubmed-meshheading:11148565-Treatment Outcome,
pubmed-meshheading:11148565-Vomiting
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Medicine, Solid Tumor Division, GI Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. oreillye@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
